CA2443144A1 - In vivo methods of determining activity of receptor-type kinase inhibitors - Google Patents

In vivo methods of determining activity of receptor-type kinase inhibitors Download PDF

Info

Publication number
CA2443144A1
CA2443144A1 CA002443144A CA2443144A CA2443144A1 CA 2443144 A1 CA2443144 A1 CA 2443144A1 CA 002443144 A CA002443144 A CA 002443144A CA 2443144 A CA2443144 A CA 2443144A CA 2443144 A1 CA2443144 A1 CA 2443144A1
Authority
CA
Canada
Prior art keywords
receptor
kdr
kinase receptor
kinase
test
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002443144A
Other languages
English (en)
French (fr)
Inventor
Kenneth A. Thomas, Jr.
Xianzhi Mao
Richard L. Kendall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2443144A1 publication Critical patent/CA2443144A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002443144A 2001-04-02 2002-03-29 In vivo methods of determining activity of receptor-type kinase inhibitors Abandoned CA2443144A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28077101P 2001-04-02 2001-04-02
US60/280,771 2001-04-02
PCT/US2002/009758 WO2002079498A1 (en) 2001-04-02 2002-03-29 In vivo methods of determining activity of receptor-type kinase inhibitors

Publications (1)

Publication Number Publication Date
CA2443144A1 true CA2443144A1 (en) 2002-10-10

Family

ID=23074563

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002443144A Abandoned CA2443144A1 (en) 2001-04-02 2002-03-29 In vivo methods of determining activity of receptor-type kinase inhibitors

Country Status (4)

Country Link
EP (1) EP1385983A4 (https=)
JP (1) JP2004527244A (https=)
CA (1) CA2443144A1 (https=)
WO (1) WO2002079498A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
AU2010232729A1 (en) 2009-03-31 2011-10-20 Arqule, Inc. Substituted indolo-pyridinone compounds
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
BRPI1010831A2 (pt) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
MX386697B (es) 2014-01-21 2025-03-19 Janssen Pharmaceutica Nv Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5783568A (en) * 1994-06-10 1998-07-21 Sugen, Inc. Methods for treating cancer and other cell proliferative diseases
US6271233B1 (en) * 1999-08-10 2001-08-07 Ciba Vision Corporation Method for treating ocular neovascular diseases

Also Published As

Publication number Publication date
JP2004527244A (ja) 2004-09-09
EP1385983A4 (en) 2005-11-16
EP1385983A1 (en) 2004-02-04
WO2002079498A1 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
CA2443144A1 (en) In vivo methods of determining activity of receptor-type kinase inhibitors
Pérez-Gutiérrez et al. Biology and therapeutic targeting of vascular endothelial growth factor A
US20250129151A1 (en) Methods for treating hepcidin-mediated disorders
Holmes et al. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition
Beyer et al. Tyrosine kinase signaling in fibrotic disorders: translation of basic research to human disease
AU2009331955B2 (en) Biomarkers for inhibitors with anti-angiogenic activity
US7175844B2 (en) Methods of modulating fibrosis
Rao et al. Role for macrophage metalloelastase in glomerular basement membrane damage associated with alport syndrome
US20140186344A1 (en) Roles for dual endothelin-1/angiotensin ii receptor (dear) in hypertension and angiogenesis
Marshall et al. The Nm23-H1 metastasis suppressor as a translational target
WO2002043759A2 (en) Method and composition for modulating bone growth
Yu et al. Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury
US20110189169A1 (en) Combination of hgf inhibitor and pten agonist to treat cancer
KR20230093429A (ko) 알킨 치환된 퀴나졸린 유도체로 암을 치료하는 방법
AU2012275346B2 (en) Predictive biomarker of survival in the treatment of renal cell carcinoma
US20060286636A1 (en) VEGF variants
US20250228826A1 (en) Combination of a gremlin-1 antagonist with an inhibitor of ras-raf-mek-erk signalling
US20040101478A1 (en) In vivo methods of determining activity of receptor-type kinase inhibitors
Beltowski et al. EGF receptor as a drug target in arterial hypertension
Bold et al. CGP 79787D (PTK787/ZK222584), CGP 84738, NVP-AAC789, NVP-AAD777 and related 1-anilino-(4-pyridyl methyl) phthalazines as inhibitors of VEGF-induced angiogenesis
US20040265970A1 (en) Don-1 gene and polypeptides and uses therefor
US7029892B1 (en) Serine threonine kinase member, h2520-59
US20030219380A1 (en) Method of determining an efficacious dose of a drug
Ahmed Mechanistic Roles of Transforming Growth Factor-Beta and Receptor Tyrosine Kinase Cross-Talks in Sprouting Angiogenesis
Blaukovitsch et al. Vasoproliferation and antiproliferative treatment options in pulmonary arterial hypertension

Legal Events

Date Code Title Description
FZDE Discontinued